Welcome to the News and Info section of the ECOG-ACRIN Cancer Research Group website. The materials posted in this section are intended to keep constituents informed about the latest news and ongoing activities of the organization. This section contains announcements, press releases, and e-newsletters. See below for news coverage.
We welcome inquiries from members of the press regarding the information posted on this website. To place a media inquiry, contact the Office of Communications.
Visit the Home Page for the latest news
New insights into cancer-related cognitive impairment help dispel notion of ‘chemo brain’ An interview with Lynne I. Wagner, PhD (Wake Forest) Healio, May 12, 2020
Vitaly Margulis, MD (U Texas Southwestern) and colleagues report on the phase two study EA8141. The results support the use of four cycles of chemotherapy consisting of methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) prior to surgery in patients with high-grade upper urinary tract cancer, a rare but treatable disease. April 4, 2020 The Journal of Urology
MRI Outperforms 3-D Mammograms In Detecting Cancer In Women With Dense Breasts NPR All Things Considered February 25, 2020
The results of Arm Z1D in the NCI-MATCH trial continue to attract media attention. Nilofer Azad, MD (Johns Hopkins) talks about the activity of nivolumab in MMR-deficient cancers in a February 20, 2020, feature article in MedPage Today/ASCO Reading Room February 02, 2020
Progress in Breast Cancer: What would Bill think? At a recent medical meeting, Joseph Sparano, MD (Albert Einstein/ Montefiore) asked what the late pioneer, William McGuire, MD, might have thought of the newest research advancements. Daniel Hayes, MD (University of Michigan) remarks in a video interview, with MedPage Today. February 18, 2020
Brian P. Schneider, MD (Indiana University) and fellow ECOG-ACRIN researchers aim to personalize chemotherapy for black women with breast cancer in a new trial, EAZ171, which is evaluating ways to reduce neuropathy, a painful side effect of chemotherapy treatments Healio HemOnc Today January 27, 2020
What have we learned lately about precision medicine? Read more about how the NCI-MATCH (EAY131) trial is helping researchers and physicians navigate the complexities of molecular profiling for targeted therapies. Journal of the National Cancer Institute January 10, 2020
Ahmad Tarhini, MD (Moffitt Cancer Center) on the results of the E1609 study: “For the first time in our knowledge in melanoma adjuvant therapy, this study has demonstrated a significant improvement in overall survival against an active control regimen.” The ASCO Post January 15, 2020
Al B. Benson III was appointed deputy chair for policy and implementation The Cancer Letter January 17, 2020
Bapsi Chakravarthy, MD (Vanderbilt) and colleagues report final results from study E5204. This phase three trial tested whether the addition of bevacizumab to mFOLFOX6, following neoadjuvant chemoradiation and definitive surgery, could improve overall survival in patients with stage II/III adenocarcinoma of the rectum. At 17% of its planned accrual, E5204 did not meet its primary endpoint. Published results inform the use of adjuvant therapy following neoadjuvant therapy. The Oncologist December 18, 2019
San Antonio Breast Cancer Symposium honors ECOG-ACRIN vice chair Joseph A. Sparano, MD with its prestigious William L. McGuire Memorial Lecture Award More Here December 01, 2020
Results from E1305, a randomized phase III trial, are published online by the Journal of Clinical Oncology on October 16, 2019. The addition of bevacizumab to chemotherapy did not improve overall survival in squamous cell carcinoma of the head and neck but improved the response rate and progression-free survival with increased toxicities. These results encourage biomarker-driven studies of angiogenesis inhibitors with better toxicity profiles in select patients.
ASCO updates guidelines for early breast cancer based on TAILORx, MINDACT trials Cancer Network July 1, 2019
One Year Post-TAILORx: Attitudes Shift and Questions Linger in Breast Cancer Recurrence Testing GenomeWeb May 31, 2019 (requires free registration)
Using Genomic Profiling to Guide Treatment Decisions for ER-Positive Breast Cancers, by Harold J. Burstein, MD, PhD CancerNetwork May 28, 2019
New TAILORx Data Provide Treatment Guidance for Women Under 50 With Early Breast Cancer The ASCO Post June 13, 2019
No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Medical Xpress June 3, 2019